Showing Results for
- All Content Types
- Magazines (801)
Search Results
- 801
Magazines
- 801
- 1From:MPR Monthly Prescribing ReferenceKarXT (xanomeline-trospium) was found to significantly reduce symptoms of schizophrenia in adult patients, according to topline results from the phase 3 EMERGENT-3 trial. KarXT is an oral, investigational therapy that...
- 2From:MPR Monthly Prescribing ReferenceHealthDay News — US health officials say they plan to investigate whether some nursing homes are falsely labeling patients as schizophrenic so they can administer sedating antipsychotic drugs to them. The Centers for...
- 3From:MPR Monthly Prescribing ReferenceThe Food and Drug Administration (FDA) has approved Rykindo® (risperidone extended-release injectable suspension for intramuscular [IM] use) for the treatment of schizophrenia in adults, and as monotherapy or as...
- 4From:Prevention (Vol. 75, Issue 1)Having a psychotic disorder such as schizophrenia could make someone two and a half times as likely to develop dementia down the line compared with a person without one, says a meta-analysis in Psychological Medicine....
- 5From:Pakistan Journal of Medical Sciences (Vol. 38, Issue 7)Byline: Shouning Peng, Changcai Liang, Shimin Deng and Yanbo Fu KEYWORDS: Schizophrenia; Tumor necrosis factor alpha; Inducible nitric oxide synthase; Cognitive impairment; Disease burden; Correlation. INTRODUCTION...
- 6From:MPR Monthly Prescribing ReferenceHealthDay News — Antipsychotic effectiveness declines in women after the age of 45 years, according to a study published online October 5 in Schizophrenia Bulletin. Iris E. Sommer, MD, PhD, from the University Medical...
- 7From:MPR Monthly Prescribing ReferenceThe Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and for maintenance...
- 8From:International Journal of Basic & Clinical Pharmacology (Vol. 11, Issue 5)Background: The rapidly expanding field of psychopharmacotherapy is challenging the traditional concepts of psychiatric treatment and research and is constantly seeking new and improved drugs to treat psychiatric...
- 9From:Skeptical Inquirer (Vol. 46, Issue 5)Back in the late 1970s and early 1980s, I worked at a residential facility for children with severe autism. These kids had been rejected from many other schools because, if left on their own, they banged their heads...
- 10From:Women's Health Weekly2022 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Mental Health Diseases and Conditions - Schizophrenia have been published. According to news reporting...
- 11From:MPR Monthly Prescribing ReferencePositive topline results were announced from a phase 3 trial evaluating the efficacy and safety of KarXT (xanomeline-trospium) for the treatment of adults with schizophrenia. KarXT is an oral, investigational therapy...
- 12From:Women's Health Weekly2022 APR 14 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on schizophrenia. According to news reporting originating from Terrassa, Spain, by NewsRx...
- 13From:MPR Monthly Prescribing ReferenceThe Food and Drug Administration (FDA) has approved Igalmi™ (dexmedetomidine) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Igalmi is an...
- 14From:Women's Health Weekly2022 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Data detailed on Oncology - Breast Cancer have been presented. According to news reporting originating from Karnataka, India, by...
- 15From:McKnight's Long-Term Care NewsDavid Blakeney died in a nursing home. Mr. Blakeney was a 63-year-old nursing home resident with dementia who died eight months after being prescribed an antipsychotic drug to address behaviors associated with dementia....
- 16
- 17From:MPR Monthly Prescribing ReferenceThe Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents 13 years of age and older. Previously, the treatment...
- 18From:MPR Monthly Prescribing ReferenceLybalvi® (olanzapine and samidorphan) is now available for the treatment of schizophrenia in adults and for bipolar I disorder in adults for acute treatment of manic or mixed episodes as monotherapy and as an...
- 19From:The New York Times MagazineThe magazine's Ethicist columnist on whether to assist a family member when they want to watch conspiracy-mongering videos. I am 50. My father and I have not been especially close for all of my adult life because of...
- 20From:Pharmacy Times (Vol. 87, Issue 10)CASE 1 TN, 35-year-old obese woman with a body mass index (BMI) of 32.4 kg/[m.sup.2] and uncontrolled type 2 diabetes is starting on an atypical antipsychotic today for the management of schizophrenia. The pharmacist...